FIELD: medicine, pharmaceutics.
SUBSTANCE: amlodipine base or its pharmaceutically acceptable salt, preferentially amlodipine besylate, bisoprolol fumarate, a disintegrating agent, a wetting agent, and if necessary additional excipients are homogenised; an antiadhesion agent is added, and the homogenisation procedure is continued; the homogenate is then tabletted by direct compression, or solid gelatine capsule is filled in; the prepared tablets or capsules are packed in moisture-proof protective packaging. The prepared tablets or capsules contain less than 0.5 wt % of active ingredients of compounds of formula
.
EFFECT: what is described is a method for preparing the stable solid pack dosage form containing the amlodipine base or its pharmaceutically acceptable salt and bisoprolol fumarate.
3 cl, 6 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
STABLE COMBINED PHARMACEUTICAL COMPOSITION | 2009 |
|
RU2687282C2 |
PHARMACEUTICAL COMPOSITION CONTAINING BETA-BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR | 2015 |
|
RU2702362C2 |
COMPOSITIONS AND METHODS OF ACTIVE PHARMACEUTICAL INGREDIENT STABILISATION | 2005 |
|
RU2391115C2 |
STABLE PHARMACEUTICAL PREPARATION CONTAINING AMLODIPINE BENZYLATE AND ATENOLOL | 1998 |
|
RU2188636C2 |
COMPOSITION INCLUDING AMLODIPINE AND LOSARTAN HAVING IMPROVED STABILITY | 2013 |
|
RU2628538C2 |
THERAPEUTIC COMBINATION OF AMLODIPINE AND BENAZEPRIL/BENAZEPRILATE | 2001 |
|
RU2292206C2 |
PHARMACEUTICAL COMPOSITION CONTAINING BETA-BLOCKER, CONVERTING ENZYME INHIBITOR AND HYPOTENSIVE AGENT OR NSAID | 2017 |
|
RU2756320C2 |
AMLODIPINE GENTISATE AND ITS OBTAINING METHOD | 2004 |
|
RU2330843C2 |
METHOD OF TREATING CARDIOVASCULAR DISEASES | 2012 |
|
RU2570752C2 |
SOLID PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPINE AND LOSARTAN | 2015 |
|
RU2698703C2 |
Authors
Dates
2015-04-27—Published
2009-09-30—Filed